AR073384A1 - Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion - Google Patents
Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacionInfo
- Publication number
- AR073384A1 AR073384A1 ARP090103591A ARP090103591A AR073384A1 AR 073384 A1 AR073384 A1 AR 073384A1 AR P090103591 A ARP090103591 A AR P090103591A AR P090103591 A ARP090103591 A AR P090103591A AR 073384 A1 AR073384 A1 AR 073384A1
- Authority
- AR
- Argentina
- Prior art keywords
- percent
- minutes
- oral dose
- pharmaceutical combination
- alisquirene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Una combinacion farmacéutica de dosis oral fija, la cual comprende: a) una cantidad terapéuticamente efectiva de alisquireno, o una sal farmacéuticamente aceptable del mismo, de preferencia la sal de hemi-fumarato del mismo, b) una cantidad terapéuticamente efectiva de amlodipina, o una sal farmacéuticamente aceptable de la misma, de preferencia la sal de besilato de la misma, en donde la combinacion farmacéutica de dosis oral fija muestra una disolucion in vitro del componente (a) del 60 por ciento o menas después de 10 minutos, y del 98 por ciento o menos después de 20 minutos, y un perfil de disolucion del componente (b) del 50 por ciento o más después de 20 minutos, y del 70 por ciento o más después de 30 minutos a un pH de 2. Reivindicacion 11: El uso de la combinacion farmacéutica de dosis oral fija de acuerdo con cualquiera de las reivindicaciones anteriores, para el tratamiento de hipertension, insuficiencia cardiaca congestiva, angina, infarto de miocardio, ateroesclerosis, nefropatía diabética, miopatía cardiaca diabética, insuficiencia renal, enfermedad vascular periférica, hipertrofia de ventrículo izquierdo, disfuncion cognitiva, embolia, dolor de cabeza, e insuficiencia cardíaca cronica, en particular hipertension.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9894508P | 2008-09-22 | 2008-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073384A1 true AR073384A1 (es) | 2010-11-03 |
Family
ID=42040192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103591A AR073384A1 (es) | 2008-09-22 | 2009-09-18 | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8613949B2 (es) |
| EP (1) | EP2328564A2 (es) |
| JP (2) | JP2012503020A (es) |
| KR (1) | KR20110060942A (es) |
| CN (1) | CN102159195A (es) |
| AR (1) | AR073384A1 (es) |
| AU (1) | AU2009292908B2 (es) |
| BR (1) | BRPI0919350A2 (es) |
| CA (1) | CA2736257A1 (es) |
| CL (1) | CL2011000594A1 (es) |
| CO (1) | CO6351711A2 (es) |
| EC (1) | ECSP11010999A (es) |
| IL (1) | IL211571A0 (es) |
| JO (1) | JO3239B1 (es) |
| MA (1) | MA32719B1 (es) |
| MX (1) | MX2011002988A (es) |
| MY (1) | MY153610A (es) |
| PE (1) | PE20110293A1 (es) |
| RU (2) | RU2014140552A (es) |
| TW (1) | TW201016217A (es) |
| WO (1) | WO2010033954A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2382969A1 (en) * | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multicoated Aliskiren formulations |
| CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
| CN103070863A (zh) * | 2011-10-25 | 2013-05-01 | 河南省健康伟业生物医药研究股份有限公司 | 阿利吉仑和氨氯地平/左旋氨氯地平的口服固体制剂的制备新工艺 |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003032954A1 (en) * | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
| HU226642B1 (en) | 2001-12-17 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Amlodipine bezylate tablets having extended stability and process for producing the same |
| NZ536555A (en) * | 2002-05-17 | 2007-03-30 | Novartis Ag | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| DE10223282B3 (de) | 2002-05-24 | 2004-02-05 | Orga Kartensysteme Gmbh | Verfahren, Computerprogramm und Computersystem für einen prepaid Telekommunikationsdienst |
| FR2853904B1 (fr) | 2003-04-15 | 2007-11-16 | Air Liquide | Procede de production de liquides hydrocarbones mettant en oeuvre un procede fischer-tropsch |
| AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| US20080161321A1 (en) * | 2004-03-17 | 2008-07-03 | David Louis Feldman | Use of Renin Inhibitors in Therapy |
| EA013053B1 (ru) | 2004-11-05 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Двуслойная таблетка, содержащая телмисартан и амлодипин |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| US20060116435A1 (en) * | 2004-12-01 | 2006-06-01 | Housel Tyler L | High strength polyurethane foam |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| PE20080991A1 (es) * | 2006-06-27 | 2008-09-05 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| WO2008033745A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| CN101594857B (zh) | 2006-11-07 | 2012-10-31 | 诺瓦提斯公司 | 阿利吉仑半富马酸盐的晶形 |
-
2009
- 2009-09-17 JO JOP/2009/0348A patent/JO3239B1/ar active
- 2009-09-18 AR ARP090103591A patent/AR073384A1/es unknown
- 2009-09-21 TW TW098131810A patent/TW201016217A/zh unknown
- 2009-09-22 US US13/063,955 patent/US8613949B2/en not_active Expired - Fee Related
- 2009-09-22 KR KR1020117009088A patent/KR20110060942A/ko not_active Application Discontinuation
- 2009-09-22 BR BRPI0919350A patent/BRPI0919350A2/pt not_active IP Right Cessation
- 2009-09-22 WO PCT/US2009/057750 patent/WO2010033954A2/en active Application Filing
- 2009-09-22 AU AU2009292908A patent/AU2009292908B2/en not_active Ceased
- 2009-09-22 PE PE2011000647A patent/PE20110293A1/es not_active Application Discontinuation
- 2009-09-22 EP EP09736332A patent/EP2328564A2/en not_active Withdrawn
- 2009-09-22 CA CA2736257A patent/CA2736257A1/en not_active Abandoned
- 2009-09-22 CN CN2009801369580A patent/CN102159195A/zh active Pending
- 2009-09-22 RU RU2014140552/15A patent/RU2014140552A/ru not_active Application Discontinuation
- 2009-09-22 MX MX2011002988A patent/MX2011002988A/es active IP Right Grant
- 2009-09-22 MY MYPI2011000931A patent/MY153610A/en unknown
- 2009-09-22 RU RU2011115712/15A patent/RU2011115712A/ru unknown
- 2009-09-22 JP JP2011528052A patent/JP2012503020A/ja not_active Withdrawn
-
2011
- 2011-03-03 IL IL211571A patent/IL211571A0/en unknown
- 2011-03-21 CL CL2011000594A patent/CL2011000594A1/es unknown
- 2011-03-25 CO CO11036957A patent/CO6351711A2/es not_active Application Discontinuation
- 2011-04-15 MA MA33780A patent/MA32719B1/fr unknown
- 2011-04-21 EC EC2011010999A patent/ECSP11010999A/es unknown
-
2014
- 2014-12-12 JP JP2014252210A patent/JP2015091830A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009292908A1 (en) | 2010-03-25 |
| EP2328564A2 (en) | 2011-06-08 |
| US20110165240A1 (en) | 2011-07-07 |
| RU2014140552A (ru) | 2015-06-20 |
| PE20110293A1 (es) | 2011-05-17 |
| JO3239B1 (ar) | 2018-03-08 |
| JP2015091830A (ja) | 2015-05-14 |
| ECSP11010999A (es) | 2011-06-30 |
| RU2011115712A (ru) | 2012-10-27 |
| CN102159195A (zh) | 2011-08-17 |
| WO2010033954A3 (en) | 2010-10-21 |
| IL211571A0 (en) | 2011-05-31 |
| CA2736257A1 (en) | 2010-03-25 |
| CL2011000594A1 (es) | 2011-08-05 |
| KR20110060942A (ko) | 2011-06-08 |
| AU2009292908B2 (en) | 2012-07-26 |
| BRPI0919350A2 (pt) | 2015-12-29 |
| JP2012503020A (ja) | 2012-02-02 |
| US8613949B2 (en) | 2013-12-24 |
| TW201016217A (en) | 2010-05-01 |
| MX2011002988A (es) | 2011-04-11 |
| CO6351711A2 (es) | 2011-12-20 |
| MY153610A (en) | 2015-02-27 |
| WO2010033954A2 (en) | 2010-03-25 |
| MA32719B1 (fr) | 2011-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
| ECSP11011030A (es) | Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
| BRPI0512193B8 (pt) | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal | |
| CL2007001870A1 (es) | Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d | |
| EA201170958A1 (ru) | Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| EA201100755A1 (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином | |
| CR8220A (es) | Composicion de fexofenadina y proceso para su preparacion | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| EA201291167A1 (ru) | Замещенные гетероциклилбензилпиразолы и их применение | |
| ECSP10010266A (es) | Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo[b,e]oxepina | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
| CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
| ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
| PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
| PE20141049A1 (es) | Composicion farmaceutica antihipertensiva | |
| AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina | |
| CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
| AR072954A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| EA201200037A1 (ru) | Терапевтические комбинации никотиновой кислоты и мелдония | |
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR085942A1 (es) | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |